Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices

Cancer Cytopathology

Volumn 123, Issue 5, 2015, Pages 282-288

  Blatt, Amy J ^a   Kennedy, Ronald ^a   Luff, Ronald D ^a   Austin, R Marshall ^b   Rabin, Douglas S ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

cervical cancer; cervical intraepithelial neoplasia 3; cotest; guideline; human papillomavirus; Papanicolaou

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ADULT; AGE; AGED; CLINICAL TRIAL; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE STUDY; CYTODIAGNOSIS; EARLY DIAGNOSIS; EVALUATION STUDY; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; RISK FACTOR; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; COHORT STUDIES; COLPOSCOPY; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84937511068     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21544     Document Type: Article

References (33)

1. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
2. Bouchard-Fortier G, Hajifathalian K, McKnight MD, Zacharias DG, Gonzalez-Golzonez LA,. Co-testing for detection of high grade cervical intraepithelial neoplasia and cancer compared with cytology alone: a meta-analysis of randomized controlled trials. J Public Health (Oxf). 2014; 36: 46-55.
3. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012; 120: 1222-1238.
4. Cox JT, Castle PE, Behrens CM, et al., Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013; 208: 184.e181-184.e11.
5. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S43-S49.
6. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM,. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011; 12: 880-890.
7. Ronco G, Dillner J, Elfstrom KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532.
8. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S56-S63.
9. Kitchener HC, Gilham C, Sargent A, et al., A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011; 47: 864-871.
10. Katki HA, Kinney WK, Fetterman B, et al., Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12: 663-672.
11. Gage JC, Schiffman M, Katki HA, et al., Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test [serial online]. J Natl Cancer Inst. 2015; 107; pii.dju153.
12. US Food and Drug Administration. FDA approves first human papillomavirus test for primary cervical cancer screening FDA [news release]. Silver Spring, MD: US Food and Drug Administration; 2014. www.fda.gov/newsevents/newsroom/pressannouncements/ucm394773.htm. Accessed September 19, 2014.
13. National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Program. SEER Program US Population Data (1969-2012). Release date, March 2014. Bethesda, MD: National Cancer Institute; 2014. www.seer.cancer.gov/statfacts/html/cervix.html. Accessed October 14, 2014.
14. Austin RM, Zhao C,. Is 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening [serial online]? Cytojournal. 2014; 11: 14.
15. Bekker JB, John TS, Leiman G,. Confirming suboptimal adherence to HPV cotesting guidelines in an academic center in Vermont. Am J Clin Pathol. 2013; 139: 259-260.
16. Tatsas AD, Phelan DF, Gravitt PE, Boitnott JK, Clark DP,. Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Pathol. 2012; 138: 223-229.
17. Smith-McCune K,. Choosing a screening method for cervical cancer: Papanicolaou testing alone or with human papillomavirus testing. JAMA Intern Med. 2014; 174: 1027-1028.
18. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER,. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force [Internet]. US Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville, MD: US Agency for Healthcare and Quality; 2011. Report No. 11-05157-EF-1.
19. Naucler P, Ryd W, Tornberg S, et al., Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009; 101: 88-99.
20. Cuzick J, Clavel C, Petry KU, et al., Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101.
21. McCredie MR, Sharples KJ, Paul C, et al., Natural history of cervical neoplasia and risk of invasive cancer in women with cervical neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9: 425-434.
22. Wu Y, Chen Y, Li L, Yu G, Zhang Y, He Y,. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol. 2006; 35: 264-269.
23. Kang WD, Kim CH, Cho MK, et al., Comparison of hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. Int J Gynecol Cancer. 2009; 19: 924-928.
24. Moreira MA, Longato-Filhio A, Taromus E, et al., Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesions. Int J Gynecol Cancer. 2006; 16: 586-590.
25. Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E,. The Abbott RealTime High Risk HPV test: comparative evaluation of analytic specificity and clinical sensitivity for cervcal carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatoven Alp Pannonica Adriat. 2009; 18: 94-103.
26. Li Z, Austin RM, Guo M, Zhao C,. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma. Arch Pathol Lab Med. 2012; 136: 1533-1540.
27. Zhao C, Li Z, Nayar R, et al., Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study. Arch Pathol Lab Med. 2015; 139: 184-188.
28. Hopenhayn C, Christian A, Christian WJ, et al., Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014; 18: 182-189.
29. American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA: American Cancer Society; 2014. www.cancer.org/acs/groups/content/@research/documents/document/acspc-041770.pdf. Accessed August 5, 2014.
30. Pirog EC, Lloveras B, Moljin A, et al., HPV prevalence and genotypes in different histologic subtypes of cervical adenocarcinoma: a worldwide analysis of 780 cases. Mod Pathol. 2014; 27: 1559-1567.
31. Huh WK, Ault KA, Chelnow D, et al., Use of primary high risk human papillomavirus testing for cervical cancer screening. interim clinical guidance. Obstet Gynecol. 2015; 125: 330-337.
32. Nayar R, Goulart RA, Tiscornia-Wasserman PG, Davey DD,. Primary human papillomavirus screening for cervical cancer in the United States-US Food and Drug Administration approval, clinical trials, and where we are today. Cancer Cytopathol. 2014; 122: 720-729.
33. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL,. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136: 189-197.